Combination Therapy with Tirzepatide and Menopause Hormone Therapy Enhances Weight Loss in Postmenopausal Women
A groundbreaking study reveals that combining tirzepatide with menopause hormone therapy significantly boosts weight loss in postmenopausal women, offering new hope for obesity management.
Recent research presented at ENDO 2025, the American Endocrine Society's annual meeting held in San Francisco, highlights a significant advancement in managing weight among postmenopausal women. The study indicates that combining the obesity medication tirzepatide with menopause hormone therapy (MHT) results in greater weight loss compared to using tirzepatide alone. The findings suggest that this combined approach could be more effective in addressing the hormonal and metabolic changes that typically lead to weight gain after menopause.
The study involved analyzing the electronic medical records of 120 postmenopausal women over an 18-month period. Among them, 40 women received both tirzepatide and MHT, while 80 women were treated with tirzepatide only. The results demonstrated that women on the combined therapy experienced an average total body weight loss of 17%, which was higher than the 14% observed in the tirzepatide-only group. Additionally, 45% of women using MHT alongside tirzepatide achieved at least a 20% reduction in total body weight—significantly more than the 18% in the non-MHT group.
Experts believe that hormonal changes during menopause contribute to increased abdominal fat, reduced muscle mass, and altered energy expenditure—factors that promote weight gain and elevate risks for heart disease and other health conditions. The combination therapy appears to counteract these changes more effectively, leading to improved weight management and associated health benefits.
Dr. Regina Castaneda from the Mayo Clinic emphasized the importance of these findings, noting that they represent the first evidence of increased treatment efficacy when pairing tirzepatide with MHT. "This opens new avenues for personalized intervention strategies to combat obesity in postmenopausal women," she said.
Further research is essential to understand the mechanisms behind this synergy and to develop accessible, tailored treatment plans for women experiencing menopause-related weight challenges. The study underscores the potential for combination therapies to enhance health outcomes and reduce the burden of obesity-related diseases among postmenopausal populations.
Source: https://medicalxpress.com/news/2025-07-combination-obesity-medication-tirzepatide-menopause.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Key Biological Traits Predict Response to CD19 CAR T Cell Therapy in B-Cell Lymphoma Patients
A large-scale study reveals how specific tumor microenvironment traits influence patient response to CD19 CAR T cell therapy in B-cell lymphoma, paving the way for personalized treatments.
Promising Drug Combination for Early Post-Myocardial Infarction Treatment
A pioneering preclinical study reveals that combining empagliflozin with sacubitril/valsartan could enhance early healing and reduce complications after a heart attack, paving the way for new treatment strategies.
Prenatal and Childhood Lead Exposure Accelerates Memory Loss in Children
New research links prenatal and childhood lead exposure to accelerated memory loss in children, highlighting the need for increased preventive measures against environmental lead hazards.
Southeast Asia Likely to Miss 2030 Targets for Ending Diseases Despite Progress Challenges
ASEAN countries face significant challenges in achieving health-related Sustainable Development Goals by 2030, with progress hindered by inequalities and weak infrastructure, though some nations show promise. Experts emphasize urgent action to bridge gaps and prevent disease burden escalation.